Information Letter on flupirtine: recall and revocation of marketing authorisation
2018.06.04
Active substance: flupirtine
Following the European benefit-risk assessment, marketing authorisations of medicinal products containing the active substance flupirtine are revoked on an EU-wide level due to the risk of liver damage.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN